10-Q: Syndax Pharmaceuticals Reports Third Quarter 2024 Results, Highlights Niktimvo Approval and Revumenib Progress

Syndax Pharmaceuticals reports a net loss of $84.1 million for the third quarter of 2024, while achieving a key milestone with the FDA approval of Niktimvo and advancing its revumenib program.

Summary

• Syndax Pharmaceuticals reported a net loss of $84.1 million for the three months ended September 30, 2024, and a net loss of $224.6 million for the nine months ended September 30, 2024.
• The company's revenue for the quarter was $12.5 million, stemming from a milestone payment related to the approval of Niktimvo.
• Research and development expenses increased to $71.0 million for the quarter and $176.1 million for the nine months, driven by the development of revumenib and axatilimab.
• Selling, general, and administrative expenses also rose to $31.1 million for the quarter and $83.2 million for the nine months, reflecting increased commercial readiness activities.
• As of September 30, 2024, Syndax had cash, cash equivalents, and short and long-term investments totaling $399.6 million.
• The company received a $350 million upfront payment in November 2024 from Royalty Pharma for a royalty agreement on Niktimvo sales.
• Syndax anticipates launching Niktimvo in the U.S. no later than early first quarter 2025.
• The PDUFA target action date for revumenib is December 26, 2024.

Sentiment

Score: 7

Explanation: The document presents a mix of positive and negative aspects. The FDA approval of Niktimvo and the progress of revumenib are positive, but the significant net losses and increasing expenses are concerning. The royalty agreement provides financial stability, but the company's reliance on future funding and the competitive landscape are risks. Overall, the sentiment is cautiously optimistic.

Positives

• The FDA approval of Niktimvo represents a significant milestone for the company and provides a new treatment option for cGVHD patients.
• The Priority Review designation for revumenib's NDA indicates the FDA's recognition of its potential to address an unmet medical need.
• The $350 million royalty funding agreement with Royalty Pharma strengthens the company's financial position.
• Positive data from the AUGMENT-101 trial of revumenib in R/R KMT2Ar acute leukemia was published in the Journal of Clinical Oncology.
• Niktimvo was added to the NCCN Clinical Practice Guidelines in Oncology as a category 2A recommendation for the treatment of cGVHD.

Negatives

• The company reported a significant net loss of $84.1 million for the third quarter of 2024 and $224.6 million for the nine months ended September 30, 2024.
• Research and development expenses increased substantially, reflecting the high costs associated with clinical trials and drug development.
• Selling, general, and administrative expenses also increased, driven by pre-commercialization activities.
• The company has an accumulated deficit of $1.1 billion as of September 30, 2024.
• The company has limited experience in generating revenue from product sales.

Risks

• The company's ability to generate revenue depends on the successful commercialization of Niktimvo and the regulatory approval of revumenib and other product candidates.
• Clinical trials are subject to delays and uncertainties, and there is no guarantee that product candidates will receive regulatory approval.
• The company relies on third-party manufacturers and Incyte for the production and distribution of its products.
• The market acceptance of Niktimvo and other product candidates is uncertain.
• The company may require additional capital to fund its operations, which may not be available on acceptable terms.
• The company faces significant competition from other biotechnology and pharmaceutical companies.
• The company is subject to various risks related to intellectual property, including potential infringement claims and challenges to patent validity.
• The company is subject to stringent and evolving U.S. and foreign laws, regulations, and rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security.

Future Outlook

The company anticipates launching Niktimvo in the U.S. no later than early first quarter 2025 and expects topline data from the AUGMENT-101 pivotal trial cohort of patients with R/R mNPM1 AML in the fourth quarter of 2024. Syndax plans to initiate a pivotal trial of revumenib in combination with venetoclax and azacitidine in newly diagnosed mNPM1 or KMT2Ar acute leukemia patients unfit to receive intensive chemotherapy by year-end 2024.

Management Comments

• The company plans to continue to leverage the technical and business expertise of our management team and scientific collaborators to license, acquire and develop additional therapeutics to expand our pipeline.
• The company plans to continue to spend a significant amount of our resources on research and development activities for the foreseeable future as we continue to advance the development of our drug candidates.

Industry Context

The approval of Niktimvo and the progress of revumenib are significant developments in the competitive landscape of oncology and hematology. The company is positioning itself to address unmet needs in cGVHD and acute leukemias, while facing competition from existing and emerging therapies.

Comparison to Industry Standards

• The increase in R&D spending is typical for a company advancing multiple clinical programs, especially in late-stage development.
• The net losses are consistent with other clinical-stage biopharmaceutical companies that are investing heavily in research and development.
• The company's cash position is relatively strong, providing a runway for continued operations and development activities.
• The royalty agreement with Royalty Pharma is a common financing strategy for companies with approved products, allowing them to monetize future revenue streams.
• The company's co-commercialization strategy with Incyte for Niktimvo is a common approach to leverage the expertise and resources of a larger partner.

Stakeholder Impact

• Shareholders: The company's financial performance and progress in drug development will impact shareholder value.
• Employees: The company's growth and success will affect job security and opportunities for employees.
• Patients: The approval of Niktimvo and the development of other product candidates will provide new treatment options for patients.
• Partners: The company's collaborations with Incyte and other partners will be crucial for the development and commercialization of its products.
• Creditors: The company's financial stability and ability to generate revenue will impact its ability to meet its obligations to creditors.

Next Steps

• Launch Niktimvo in the U.S. no later than early first quarter 2025.
• Report topline data from the AUGMENT-101 pivotal trial cohort of patients with R/R mNPM1 AML in the fourth quarter of 2024.
• Initiate a pivotal trial of revumenib in combination with venetoclax and azacitidine in newly diagnosed mNPM1 or KMT2Ar acute leukemia patients unfit to receive intensive chemotherapy by year-end 2024.
• Continue the Phase 2 trial of axatilimab on top of standard of care in patients with IPF (MAXPIRe trial).
• Continue to develop and commercialize revumenib and axatilimab.

Key Dates

Keywords

Niktimvo, axatilimab, revumenib, cGVHD, KMT2Ar, AML, ALL, FDA approval, clinical trials, biopharmaceutical, oncology, hematology, mennin inhibitor, CSF-1R inhibitor